## **SANDOZ GROUP AG CHF0.05**

ISIN: CH1243598427 WKN: 124359842 Asset Class: Stock



#### **Company Profile**

Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. It acquires, manages and sells investments and intellectual property in the healthcare and medical device industry and conducts all business at home and abroad. The firm can acquire, sell, debit and manage interests in other companies, intellectual property rights and real estate at home and abroad, as well as establish branches and subsidiaries at home and abroad. The company was founded on January 17, 2022 and is headquartered in Rotkreuz, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity	
Current assets	6,372,973,000		5,528,995,000		5,070,549,000		
Common stock capital		20,199,000		-		-	
Fixed assets	9,980,285,000		10,714,741,000		10,912,843,000		
Equity capital of a company		7,283,639,000		8,104,752,000		7,437,717,000	
Cash and cash equivalents	933,389,000		68,464,000		36,446,000		
Accrued liabilities		372,009,000		343,249,000		434,618,000	
Other assets	-		-		-		
Current liabilities		4,795,721,000		7,322,032,000		7,621,769,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		4,273,898,000		816,951,000		923,906,000	
Different income		-		-		-	
Other liabilities		129,614,000		99,921,000		112,071,000	
Total assets	16,353,259,000	16,353,259,000	16,243,736,000	16,243,736,000	15,983,393,000	15,983,393,000	

#### **Balance notes**

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	20,000	-	-
Equity ratio	44.59%	49.96%	46.59%
Debt-equity ratio	124.29%	100.15%	114.63%

### **Others**

	2023	2022	2021
Tax Expense Rate	38.46%	22.87%	30.69%

# **SANDOZ GROUP AG CHF0.05**

ISIN: CH1243598427 WKN: 124359842 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	8,940,686,000	8,859,184,000	8,794,328,000
Net income	69,196,000	809,895,000	830,153,000
EBIT	286,876,599	1,201,248,622	1,337,697,468
Operating income before taxes	116,824,000	1,052,481,000	1,200,431,000
Cash Flow	325,311,000	1,168,044,000	1,237,916,000
Net interest income	-152,770,000	-76,405,000	-56,684,000
Research and development expenses	832,151,000	795,569,000	832,896,000
Income taxes	44,932,000	240,676,000	368,449,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	475,689	-	-

Board of Directors	
Aarti Shah	Member of the administrative board
Karen Hübscher	Member of the administrative board
Mathai Mammen	Member of the administrative board
Shamiram Feinglass	Member of the administrative board
Graeme Pitkethly	Member of the administrative board
Ioannis Skoufalos	Member of the administrative board
Maria Rosaria Varsellona	Member of the administrative board
Michael Rechsteiner	Member of the administrative board
Urs Riedener	Member of the administrative board
Gilbert Ghostine	Chairman of the administrative boar

Members of Management Board			
Richard Saynor	Chairman of Managing Board		
Claire D'Abreu-Hayling	Member of Executive Committee		
Colin Bond	Member of Executive Committee		
Francisco Ballester	Member of Executive Committee		
Ingrid Sollerer	Member of Executive Committee		
Keren Haruvi	Member of Executive Committee		
PhD Glenn A. Gerecke	Member of Executive Committee		
Pierre Bourdage	Member of Executive Committee		
Rebecca Guntern	Member of Executive Committee		
Tripti Jha	Member of Executive Committee		